if the results were bad and one person in the company knew the results this stock would tank on massive volume. This is some nervous nellies who were gifted shares in their estates taking precautions. I for one bought today at 5.9
As per Dr A ,at his recent investor conference and posted here, results will be released in January. In this no news vacuum, the stock is cycling betweeen 6-7. Unless the volume picks up substantially I would not worry! IMHO
Correct. I have approximately 65 K shares, I had 120 K but sold them all after the stock plunged to 4.5 and recovered and then built up a position. The risk in my mind is not only that the trial will not be successful but the degree of relief. Unless there is 6-8 point improvement in the AUA score, the stock will tank.
How do you hedge 140000 shares; and 60,000 calls. If I am not mistaken that is what you said you have. Sympathize with your IMUC loss; hopefully NWBO will do better.
With the way this company functions we will need all the good luck, we can get. No PR as yet from the company regarding trial completion.
With all the negative attention with THOR , I think all devices placed in contact with the circulation have little to no chance of being approved for Stage 3 HF and I think sooner or later the market will realize that for this subgroup SSH is the only realistic option nearing approval.
I am not going to caught up debating anything with you as that is what you crave- somebodywho takes you seriously. No wonder SSH is going up and Thor tanking as it elminates THOR as a competitor for stage 3 HF. Did you say you sold THOR and bought SSH? LOL
Ask your cats to research the mortality and morbidty rate of an INR between 2-3 and then use your cut and paste skills.It shouldgive you a glimpse into how doctors think. As for the name calling, you started it.
#$%$ yopur thinking is important only to you and yourcats. Stop Polluting the SSH and THOR Boards with your overblown self important garbage.
Listen you bigmouthed low IQ purveyor of garbage; I do not usually indulge in personal attacks specially on mentally challenged, social outcasts but you do not have the brains or iq to head any research team unless you mean your cats. Your thinking is narrow and strait jacketed just like you should be.
Ahead of the Bell: Thoratec slumps on study
Thoratec falls after study says rate of blood clots in HeartMate II patients is increasing
November 29, 2013 9:12 AM
If you think Bigs pollutes this Board, go and have a look at the THOR Board.
NEW YORK (AP) -- Shares of Thoratec fell 11 percent in premarket trading Friday after a study found that the rate of blood clots in patients implanted with its HeartMate II pump is increasing.
A study by the Cleveland Clinic found that starting on March 1, 2011, 8.4 percent of patients who received a HeartMate II pump suffered a blood clot within three months of implantation. Before that date, 2.2 percent of patients experienced a blood clot within the first three months. Results from the study were taken from three medical centers, and the data were published Wednesday in the New England Journal of Medicine.
Thoratec Corp. did not immediately respond to a request for comment.
HeartMate pumps are used in patients who are waiting for a heart transplant or in those too sick for heart transplant surgery. In 2013 about 90 percent of Thoratec's revenue has come from sales of HeartMate products.
The company's shares lost $4.62 to $37.50 in premarket trading after closing at $42.12 on Wednesday
Since you are spending so much time and effort on the ejection fraction, let me give you a tip. Absolute numbers in ejection fractions do not translate into actual physical performance. As per social security if you have an ejection fraction less than 30%, only then can you can qualify for disability. Most people with ejection fractions above that level manage to lead fairly comfortable albeit more sedentary lives.
I understand your "personality" and I have no intention of engaging in a prolonged, useless debate with you. Take this fwiw.
I have been studying the results of the previous phase two studies with NX1207 and in the first phase two study the lower dose was found to better and 2.5 ml the lower dose was chosen for the second phase two and I believe the phase three trials. I wonder why the lower dose was more effective than the higher doses? Any guesses?
All three doses of NX-1207 showed therapeutic effect at the study’s primary endpoint (90 days after treatment) with the mean improvement in AUASI score ranging from 11.0 (2.5 mg; p = 0.008 when compared with placebo) to 8.7 (5.0 mg; p = 0.08) to 8.1 (10 mg; p = 0.17) with a total pooled improvement of 9.35 (p = 0.017). Subjects receiving NX-1207 had mean prostate glandular volume (PGV) reduction of 6.8 ml in the transition zone (p
Since NWBO processes the antigens from the tumor directly they should be able to hit more antigens and have better outcome theoretically.
One fact no one has mentioned is that they were about to run out of money. I believe they were down to less than 2 million and had no choice in the timing of the deal.